TLRY
Tilray Brands Inc
NASDAQ · Pharmaceuticals
$7.58
+0.53 (+7.52%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 107.48M | 98.30M | 199.10M | 180.40M | 169.99M |
| Net Income | -286,152,641 | -235,538,116 | 47.16M | 49.45M | 42.44M |
| EPS | — | — | — | — | — |
| Profit Margin | -266.3% | -252.9% | 23.7% | 27.4% | 25.0% |
| Rev Growth | +9.3% | +9.3% | +4.2% | -1.4% | +19.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 73.69M | 73.69M | 373.30M | 368.43M | 383.92M |
| Total Equity | 367.88M | 367.88M | 623.84M | 614.67M | 608.97M |
| D/E Ratio | 0.20 | 0.20 | 0.60 | 0.60 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -283,472,982 | -246,295,347 | 106.10M | 94.91M | 94.57M |
| Free Cash Flow | — | — | 63.55M | 60.57M | 46.11M |